Biotechnology

Amylin pharmaceuticsClient s NameAmylin Pharmaceuticals Founded : 19879360 Towne Centre Drive IPO : 1992San Diego , California 92121 http /network .amylin .comNASDAQ : AMLNSIC : - Pharmaceutical preparations (PrimaryNAICS : 325412 - Pharmaceutical Preparation Mfg (PrimaryLine of Business : BiotechnologySummary FinancialsFiscal Period : Q3End fancy : celestial latitude 31 , 2010State Reporting Unit : ThousandsSummary Income Summary offset piece of paper measure Revenues : 758 ,419 entirety Current Assets : 843 ,303 add Operating Expense : 173 ,347 Total Assets 1 ,675 ,774Net Income (after taxes (186 ,256 ) Total Current Liabilities : 300 ,797Basic /Diluted EPS : NA Total Long Term Debt : 673 ,919Quarterly Revenue Growth : -3 .50 Total Liabilities : 1 ,254 ,123Total Equity : 421 ,651Summary Cash Flow Total un couth Shares cracking : 143 .62MCash from Operating Activities (19 ,923 ) Total Cash /Share : 4 .

17Cash from spend Activities : 116 ,072 Total Debt /Equity : NACash from Financing Activities : 20 ,289Net counterchange in Cash : 116 ,438P /E (intraday :N /AEPS : -1 .25Beta : 1 .72Market capitalisation 2 .66BMost Recent Closing Price : 18 .47 , July 19thHigh : 24 .21 unhopeful : 11 .01Principle BusinessAmylin Pharmaceuticals , Inc . engages in the discovery , development , and commercialisation of medicate candidates for the handling of diabetes obesity , and other diseasesProductsBYETTA (exenati de ) injection for the treatment of persona! 2 diabetesSYMLIN (pramlintide acetate ) injection for the treatment of eccentric person 1 and type 2 diabetesR D ProductsDiabetes : Exenatide erstwhile hebdomadary , exenatide once weekly pen , exenatide suspension formulation , exenatide nasal bone , and...If you lack to get a full essay, order it on our website: OrderCustomPaper.com

If you want to get a full essay, visit our page: write my paper